News
AZ’s COVID-19 vaccine trial resumes in Japan
A phase I/II clinical trial for AstraZeneca’s Oxford University-partnered COVID-19 vaccine AZD1222 has resumed in Japan, following the restart of trials in the UK, Brazil, South Africa and India.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
A phase I/II clinical trial for AstraZeneca’s Oxford University-partnered COVID-19 vaccine AZD1222 has resumed in Japan, following the restart of trials in the UK, Brazil, South Africa and India.